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ARTICLE
Combination of pharmacotherapy and lidocaine 
analgesic block of the peripheral trigeminal 
branches for trigeminal neuralgia: a pilot study 
Combinação de farmacoterapia e bloqueio analgésico com lidocaína sobre os ramos 
periféricos trigeminais no tratamento da neuralgia do trigêmeo: um estudo piloto
Fabrizio Di Stani1 , Christine Ojango2 , Demo Dugoni1 , Luigi Di Lorenzo3 , Salvatore Masala2 , Roberto Delfini1 , 
Gianluca Bruti1, Giovanni Simonetti2,  Elcio Juliato Piovesan4, Andrea Gennaro Ruggeri1
Classical trigeminal neuralgia (CTN) is a disorder char-
acterized by recurrent unilateral brief electric shock-like 
pains, abrupt in onset and termination, limited to the distri-
bution of one or more divisions of the trigeminal nerve and 
triggered by innocuous stimuli. There may or may not be, 
additionally, persistent background facial pain of moderate 
intensity. In general, the recurrent episodes prevail for a few 
seconds, although the duration of pain clusters may extend 
up to 2 minutes1. The episodes are caused by trivial non-
nociceptive stimuli, including eating, yawning, touching, 
feeling cold or warm2,3,4. The CTN patients describe “trigger 
zones” or specific facial areas, where these stimuli provoke 
pain2. CTN developes without apparent cause other than 
neurovascular compression1.
The incidence of CTN is 4-5 per 100,000 persons per year 
and the disorder is more common in females over 50 years3,4,5.
The evidence of pressure to the trigeminal nerve from a 
vascular structure in CTN has been shown in various cases 
with imaging findings of artery crossing the nerve and/or pro-
voking displacement3. In addition, intra-operative recordings 
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AbstrACt 
Classical trigeminal neuralgia (CTN) is treated predominantly by pharmacotherapy but side effects and unsuccessful occurs. The current 
study was carried out to evaluate the therapeutic effect of combination of pharmacotherapy and lidocaine block. Thirteen patients with CTN 
managed with pharmacotherapy were recruited and assigned either to no additional treatment (Group I) or to additional analgesic block 
(Group II). The primary endpoint was the reduction in the frequency of pain episodes in a month assessed at 30 and 90 days. Comparisons 
of measurements of pain, general health and depression scales were secondary endpoints. The results from the follow-up visits at 
30 and 90 days showed the Group II to have larger reduction in the frequency of pain and exhibited a bigger improvement in the scores 
of the pain, general health and depression scales. The results from this preliminary study suggest a clinical benefit of the combination of 
pharmacotherapy and lidocaine block. 
Keywords: analgesic block, classical trigeminal neuralgia, lidocaine, treatment. 
resumo
A neuralgia clássica do trigêmio (NTC) é tratada predominantemente por drogas, porém efeitos colaterais e falhas terapêuticas ocorrem. 
Avaliamos o efeito terapêutico da combinação entre farmacoterapia e bloqueio analgésico utilizando a lidocaína. Treze pacientes 
portadores de NTC tratados com farmacoterapia foram divididos em dois grupos: Grupo I pacientes que mantiveram somente tratamento 
medicamentos e Grupo II pacientes que associaram bloqueio anestésico. O objetivo primário do estudo foi à redução da freqüência da dor 
30 e 90 dias após o bloqueio. Secundariamente avaliamos o impacto sobre as escalas de depressão, dor e qualidade de vida. O grupo II teve 
uma redução significativa na freqüência da dor e uma melhora nos escores de qualidade de vida, dor e escala de depressão. Os resultados 
sugerem um benefício clinico da combinação de farmacoterapia e bloqueio anestésico no tratamento da NTC. 
Palavras-chave: bloqueio analgésico, lidocaína, neuralgia trigeminal clássica, tratamento. 
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and the clinical improvement after de-compression are evi-
dences of the presence of neurovascular conflict2. The pres-
sure to the nerve is thought to cause de- and remyelination 
with the resulting of increased nerve excitability and mani-
festation of pain impulses3.
The first-line treatment for CTN pain is carbamaze-
pine and oxcarbazepine6. Other anticonvulsants, such as 
lamotrigine, and the muscle relaxant baclofen are used as 
second-line therapy2. In about 30% of cases the pharmaco-
logical approach is not sufficient to control pain. The phar-
macotherapy may produce side-effect, commonest being 
drowsiness, ataxia and decrease mental acuity5. The surgi-
cal management approaches include decompression of the 
trigeminal nerve or lesioning of the nerve or trigeminal gan-
glion2. The choice of the surgical management depends on 
patient’s age and co-morbidities, duration of symptoms and 
on the response to the pharmacotherapy, as procedure-relat-
ed complications have been reported with sensory deficit be-
ing the most common6.
As an alternative management, trigeminal nerve block 
with local anaesthetics could be considered in combina-
tion with pharmacotherapy7,8. The scope of this study was 
to evaluate the clinical benefit of combination of pharma-
cotherapy and lidocaine analgesic block in CTN patients. 
Thus, this preliminary study attempts to generate hypoth-
eses for future randomised controlled study to evaluate the 
efficiency of combination therapeutic approach in CTN 
pain management.
metHoD
study design and patients
All subjects seen for the first time between may 2008 
and september 2009 were recruited from the out-patient 
neurosurgery department of the general hospital of the 
University of Rome “La Sapienza”. All enrolled patients were 
diagnosed with CTN according to the IHS 2004 criteria9 and 
were retrospectively confirmed to be eligible according to 
IHS criteria 20131. Patients with symptomatic trigeminal 
neuralgia were not included to the study. Additional exclu-
sion criteria were age < 18 years, diabetes mellitus or intol-
erance to glucose, cardiac arrhythmias, coagulation dis-
eases, pregnancy or lactation and sensibility to lidocaine. 
Ethics committee approval was acquired before the start 
of the study and all patients gave written informed consent 
before the enrolment.
Procedure
All patients were started with or were already previous-
ly on the pharmacological therapy for the trigeminal neu-
ralgia. Patients were randomly assigned to one of the two 
following treatment groups. Patients in Group I were treat-
ed over the whole study period only with pharmacological 
medications. In Group II, patients received in addition to 
their per os medication one injection of lidocaine to the 
trigger points. After the initial visit and conformation of eli-
gibility, patients enrolled into Group II, were given the ap-
pointment for the analgesic block with lidocaine injection. 
The treatment procedure of analgesic block of the periph-
eral trigeminal branches was performed with 2-4 cc of 2 % 
lidocaine. The injection was done in supine position with 
vertebral column in neutral position. After the application 
of the antiseptic on the area of interest, the injection with li-
docaine was performed on one or on several levels of the ex-
its of the three branches of the trigeminal nerve (V1, supra-
orbital foramen; V2, infraorbital foramen; V3, mandibular 
foramen). After the procedure patients were monitored for 
1 hour for early complications and subsequently discharged 
from hospital.
evaluations
The patients were assessed 3 times during the study du-
ration. The first visit (T = 0) was followed by a second visit at 
30 days (T = 1) and a third visit at 90 days (T = 2) after the be-
ginning or modification of the pharmacotherapy (Group I) or 
after lidocaine injection (Group II). The first visit (T = 0) was 
consisted of the assessment of neurological status and the 
evaluation of pain and quality of life scales in patients eligi-
ble for the study. Baseline evaluations of routine blood tests, 
electrocardiography and neuroradiological evaluation with 
magnetic resonance and magnetic resonance angiography 
with arterial and venous phase were performed. The latter 
imaging data was acquired to exclude symptomatic trigemi-
nal neuralgia and the final confirmation of eligibility was as-
sessed according to the imaging data. During the follow-up 
visits T = 1 and T = 2 patients in both groups were assessed 
for the frequency of pain episodes in a month and with qual-
ity of life, depression and intensity of pain scales. The follow-
ing scales as measures were recorded during the initial and 
the follow-up visits: The Medical Outcomes Trust 36-Item 
Short Form Health Survey (SF-36®), Brief Pain Inventory (BPI) 
and Beck Depression Inventory (BDI). All of these scales have 
been well validated and used extensively in clinical trials and 
pain management.
Case series analysis
Descriptive statistics including mean and standard de-
viation (SD) were calculated for demographic and clinical 
characteristics of the study patients in both groups. The 
outcome measures for each patient was the frequency of 
pain attacks in a month measured at T = 1 and T = 2 and 
expressed as a percentage relative to the baseline (0%- free 
from attacks; 100% same frequency of attacks as at base-
line) and measures on the assessment scales. The patients 
were asked to report any adverse effects to the physician 
during the follow-up visits.
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resuLts
Thirteen patients with classical trigeminal neuralgia, who 
met the IHS 2004 criteria9, were recruited. All patients seen 
were offered to participate and none declined or dropped 
out. Seven patients were allocated to Group I, in which pa-
tients received only pharmacological treatment for CTN pain 
during the whole study duration. In Group II six patients un-
derwent regional analgesic block of the peripheral trigemi-
nal branches in addition to their pharmacotherapy. The gen-
eral characteristics of patients in Group I and Group II are 
summarized in Table 1. Table 2 shows the results of the base-
line assessments of SF-36®, BPI and BDI scales separately in 
both groups. Pharmacotherapy was not the same in all the 
patients, although carbamazepine was the commonest drug 
prescribed to the study patients, followed by oxcarbazepine, 
gabapentin and lamotrigine.
At the first follow-up visit (T = 1) at 30 days patients in 
Group I reported more pain episodes in a month (mean 
18.11 ± 10) than patients in Group II (mean 8.33 ± 5,.16). 
Similarly, during the second follow-up visit at 90 days there 
was an evident difference of frequency of pain attacks be-
tween Group I (mean 22.1 ± 9.9) and Group II (mean 6.5 ± 7.1). 
A side-by-side group comparison on individual subjects was 
made and the absolute frequency measures in follow-up 
studies were adjusted with baseline measurements in all pa-
tients, in order to visualise the residual pain. In Figure 1 the 
frequency of pain attacks in a month expressed as a percent-
age relative to the baseline (0%- free from attacks; 100% same 
frequency of attacks as at baseline) for all patients in both 
groups is shown. As seen in the Figure 1 patients in Group 
I had smaller pain frequency changes from the baseline in 
both follow-up visits, while patients in Group II the changes 
were bigger. The average of the frequency of pain attacks in a 
month expressed as a percentage relative to the baseline or 
residual pain in both groups is presented in Figure 2.
The results of SF-36®, BPI and BDI scales showed the ten-
dency of improved scores in the group who received the 
table 1. Baseline characteristics and clinical data of study patients.
Demographic characteristics of study patients.
Group I Group II
Age (years) Mean ± SD 63.0 11.8 68.2 10.8
Gender Women n % 4 57.1 4 66.7
Duration of symtoms 
(years)
Mean ± SD 5.0 2.90 16.8 9.20
Symtomatic facial side Right n % 2 28.6 3 50
Left n % 5 71.4 3 50
Pain location 
(trigeminal branches) 
V2 or V3 n % 3 42.9 3 50
V1 + V2 or V2 + V3 n % 4 57.1 2 33.3
V1 + V2 + V3 n % 0   1 16.7
Frequency of pain 
attacks 
dd/month 30   28.3  
SD: standard deviation; n: number of patients; dd/month: days 
per month.
table 2. Baseline assessment of SF-36®, BDI and BPI scales.
 
 
Group I Group II
Mean ± SD Mean ± SD
SF-36 physical functioning 50.7 35.76 66.7 26.39
SF-36 physical role functioning 25.7 36.56 25 38.73
SF-36 bodily pain 25.9 14.38 39.8 21.18
SF-36 general health perceptions 38.6 19.32 46 11.88
SF-36 vitality 43.1 18.37 50 14.83
SF-36 social role functioning 39.2 25.45 52 14.71
SF-36 mental health 34.3 25.81 60.7 19.66
SF-36 emotional role functioning 19.6 26.59 38.9 49.07
BDI 26.7 16.18 14 11.24
BPI severity index 5.1 1.999 5.3 2.558
BPI interferference index 4.3 1.599 3.4 3.354
Baseline assessment of The Medical Outcomes Trust 36-Item; 
SF-36®: Short Form, Health Survey; BDI: Beck Depression 
Inventory; BPI: Brief Pain Inventory scales.
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Figure 1. Frequency of pain attacks in a month measured at T = 1 and T = 2 expressed as a percentage relative to the 
baseline (0%- free from attacks; 100% same frequency of attacks as at baseline) in all patients. Brown: follow-up visit T = 1; 
Green: follow-up visit T = 2.
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combination treatment during both follow-up visits of T = 1 
and T = 2. The Figure 3 represents the values of the assess-
ment scales during the follow-up visit 30 days post-injection. 
Figure 4 represents the scores after 90 days. Group I had in 
all of the SF-36® sections smaller scores and in Group II the 
scores were higher, thus patients in Group II exhibited less-
er disability and better emotional and physical functioning. 
Although, the BPI and BDI results did not differ remarkably, 
the tendency of lower depression and pain scores in Group 
II was noted. No systemic reactions were recorded and no 
injection-related adverse events of haematoma, itching or 
pain at the site of injection was reported.
Due to the small number of patients the statistical analy-
sis was not done to evaluate the differences in frequency of 
pain episodes in a month and to evaluate the values of the 
assessment scales.
DIsCussIoN
The scope of the present study was to evaluate the effi-
cacy of combination therapy of pharmacological treatment 
and the trigeminal nerve block with lidocaine in patients 
with classical trigeminal neuralgia. The previous studies with 
combination therapy of pharmacological treatment and an-
algesic injections for peripheral branches of the trigemi-
nal nerve pain management have shown promising results. 
Han  et  al., evaluated high concentration of lidocaine for 
trigeminal nerve block in patients with TN7. Eleven of 35 pa-
tients in the cited study experienced complete pain relief and 
general pain scores following the analgesic block were mark-
edly reduced compared to pre-treatment scores. The other 
study by Lemos et al. evaluated the protocol of gabapentin 
in association with ropivacaine block8. The clinical benefit 
in this combination management was found to be improve-
ment of visual analogue scores (VAS) of pain until 28 days 
after the treatment. The results of the present study with in-
jections of 2% lidocaine are in accordance with these previ-
ous studies of using local analgesic drug as a complementary 
treatment for pain management in CTN patients. Our study 
showed reduced frequency in both of the study groups, but 
more evident in the group which received the combination of 
pharmacological treatment and analgesic injection. In addi-
tion, in the present study patients treated with combination 
therapy presented in follow-up visits with improved quality 
of life (as assessed with several SF-36® scores), with less pain 
(as assessed with BPI scale) and with less depression (as as-
sessed with BDI scores).
The effect of the combination therapy was evident in both 
follow-up studies of 30 days and 90 days. In clinical practice 
lidocaine is used as a local anaesthetic due to its rapid onset 
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Figure 4. Assessment of scales at T = 2. Brown: Group I;  
Green: Group II. SF-36 dimensions: SF-PF - physical 
functioning, SF-PRF - physical role functioning, SF-BP - bodily 
pain, SF-GHP- general health perception, SF-V- vitality, 
SF-SRF - social role functioning, SF-ERF - emotional role 
functioning, SF-MH - mental health, BDI- Beck Depression 
Inventory, BPI-SI - Brief Pain Inventory Severity Index, 
BPI-II - Brief Pain Inventory Interference Index.
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Figure 3. Assessment of scales at T = 1. Brown: Group I;  
Green: Group II. SF-36 dimensions: SF-PF - physical 
functioning, SF-PRF - physical role functioning, 
SF-BP - bodily pain, SF-GHP- general health perception, 
SF-V- vitality, SF-SRF - social role functioning, SF-ERF - 
emotional role functioning, SF-MH - mental health, BDI- Beck 
Depression Inventory, BPI-SI - Brief Pain Inventory Severity 
Index, BPI-II - Brief Pain Inventory Interference Index.
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Figure 2. The average frequency of pain attacks in a month 
measured at T = 1 and T = 2 and expressed as a percentage 
relative to the baseline (0%- free from attacks; 100%- same 
frequency of attacks as at baseline) in both groups.
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and relatively short duration of the pharmacological action. 
The mechanism of the prolonged analgesic effect of the lido-
caine injections, however, is not entirely clear. The prolonged 
effect of lidocaine injections on CTN has been described also 
in the study by Han et al.. In that study the pain free inter-
val after the nerve block was from 3 weeks up to 172 weeks7. 
The longer duration effect of the local analgesic is assumed to 
be partly due to the physical action of the analgesic drug by 
clearing adhesions or inflammatory exudates from the vicin-
ity of the nerve7.
Several limitations of the study should be mentioned. 
First, the study included a very small number of patients. This 
is due to fact that classical trigeminal neuralgia is relatively 
rare disorder. Furthermore, patients who were recruited from 
pain centers exhibited facial neuralgia symptoms already for 
many years. In standard clinical practice the first-line phar-
macological medical treatment is offered for CTN patients 
and most of patients who were recruited had developed re-
fractory to the first-line treatment. It would be of interest to 
evaluate the combination therapy also in the initial phase of 
the disease. Due to the small number of recruited patients 
into the study no specific statistical analyses was performed 
and the results were evaluated qualitatively as case series in 
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this preliminary study. The qualitative results, however, are 
encouraging in order to set-up an extended study with ran-
domised controlled trial.
In most CTN cases the pharmacological treatment is ef-
fective in the initial phase and the pharmacological treat-
ment is usually maintained until it is effective. However, 
the pharmacological medication is not sufficient in all pa-
tients and over the course of the disease patients may de-
velop refractoriness to the pharmacological treatment and 
often patients seek the alternative methods for their pain 
management. As the procedure of lidocaine analgesic injec-
tion is simple and safe, it can be recommended for patients, 
whose pain is not controlled sufficiently with only pharma-
cological drugs or to patients who have contra-indications 
for surgical intervention.
In conclusion, the combination of pharmacological ther-
apy and lidocaine analgesic block of peripheral branches of 
the trigeminal nerve were able to achieve considerably lesser 
frequency of CTN pain attacks in a month than pain man-
agement with only the pharmacological therapy. In addition, 
to the reduction of frequency of CTN pain crises, the results 
showed consistent reduction of pain and improvement in the 
quality of life in the follow-up visits up to 90 days.
